LAS VEGAS, Oct. 26 /PRNewswire/ — Cord Blood
America, Inc. (http://www.cordblood-america.com)
(OTC Bulletin Board:
CBAI), the umbilical cord blood stem cell
preservation company focused on bringing the life saving
potential of stem cells to families nationwide and internationally,
today announced its Chairman, CEO and co-founder, Matthew
Schissler, has updated progress on the Company’s stem cell
collection business in China in an interview with analyst Francis
Gaskins.

The entire interview is available at:  http://gaskinsco.com/cbai-10-25-10.mp3.

In the interview, Mr. Schissler explains some changes to the
structure of the transaction since the original announcement on
March 31, 2010.  

Several parties, including Cord Blood America, have formed a new
company, China Stem Cells, Ltd., to oversee the project.  Mr.
Schissler will serve as President of the new company.

Cord Blood America will provide advisory and consulting
expertise, proprietary technology and know-how on the processing
and storage of stem cells, for which it will receive royalties and
an equity stake.  The new company already is completing a
laboratory in China for stem cell storage, with storage expected to
begin in late 2010 or early 2011.  Plans are moving forward to
build a larger laboratory in China within two years.

“This is a more cost effective, smoother process and it gives
Cord Blood America a strategic footprint into the Far East,” Mr.
Schissler said.  He explained that the Chinese are storing
stem cells at rates faster than the U.S. and Europe.

About Cord Blood America

Cord Blood America is the parent company of CorCell, which
facilitates

‘/>”/>

SOURCE